LivaNova PLC

178 articles about LivaNova PLC

• LivaNova to Present at the Piper Sandler Healthcare Conference

  11/9/2023

  LivaNova PLC, a market-leading medical technology company, announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Piper Sandler Healthcare Conference in New York.

• LivaNova Reports Third-Quarter 2023 Results

  11/1/2023

  LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance.

• LivaNova to Present at the Stifel and Wolfe Healthcare Conferences

  10/25/2023

  LivaNova PLC announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business update during fireside chats at two healthcare conferences in New York in November.

• LivaNova Board Appoints J. Christopher Barry as New Director

  10/6/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.

• LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023

  9/21/2023

  LivaNova PLC, a market-leading medical technology company, announced that Marco Dolci intends to retire as President of the Cardiopulmonary Business Unit by December 31, 2023.

• LivaNova to Announce Third-Quarter 2023 Results

  9/20/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Time).

• LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

  8/30/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.

• LivaNova to Present at the Baird Global Healthcare Conference

  8/24/2023

  LivaNova PLC, a market-leading medical technology company, announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Baird Global Healthcare Conference in New York.

• LivaNova Reports Second-Quarter 2023 Results

  7/26/2023

  LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance.

• LivaNova to Announce Second-Quarter 2023 Results

  6/14/2023

  LivaNova PLC, a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m. London time.

• LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study

  6/13/2023

  LivaNova PLC announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy™ System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.”

• LivaNova Reports First-Quarter 2023 Results

  5/3/2023

  LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.

• LivaNova Board of Directors Announce Leadership Changes

  4/14/2023

  LivaNova PLC, a market-leading medical technology and innovation company, announced that Damien McDonald has resigned as Chief Executive Officer.

• LivaNova to Announce First-Quarter 2023 Results

  3/22/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m. London time (8 a.m. Eastern Time).

• LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures

  3/9/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM).

• LivaNova to Present at the Barclays Global Healthcare Conference - March 09, 2023

  3/9/2023

  LivaNova PLC, a market-leading medical technology and innovation company, announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.

• LivaNova Reports Fourth-Quarter and Full-Year 2022 Results

  2/22/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.

• LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures

  2/8/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*.

• LivaNova Launches SenTiva DUO

  2/2/2023

  LivaNova PLC, a market-leading medical technology and innovation company, launched SenTiva DUO™, an implantable pulse generator with a dual-pin header to provide VNS Therapy™ for the treatment of drug-resistant epilepsy.

• LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results

  1/18/2023

  LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February 22, 2023 at 1 p.m. London time (8 a.m. Eastern Time).